A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors

Drilon, A; Nagasubramanian, R; Blake, JF; Ku, N; Tuch, BB; Ebata, K; Smith, S; Lauriault, V; Kolakowski, GR; Brandhuber, BJ; Larsen, PD; Bouhana, KS; Winski, SL; Hamor, R; Wu, WI; Parker, A; Morales, TH; Sullivan, FX; DeWolf, WE; Wollenberg, LA; Gord

Rothenberg, M (reprint author), Loxo Oncol Inc, 281 Tresser Blvd,9th Floor, Stamford, CT 06901 USA.; Hyman, DM (reprint author), Mem Sloan Kettering Canc Ctr, 300 E 66th St,Room 1353, New York, NY 10065 USA.

CANCER DISCOVERY, 2017; 7 (9): 963

Abstract

Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion-positive canc......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索